


Healthcare News Roundup: Oncology
HSMN NewsFeed - 26 Apr 2021
Accuray Appoints Jean-Philippe Pignol, M.D., Ph.D. as Chief Medical & Technology Officer
Accuray Appoints Jean-Philippe Pignol, M.D., Ph.D. as Chief Medical & Technology Officer
HSMN NewsFeed - 19 Apr 2021
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
Curis Receives FDA Orphan Drug Designation for CA-4948 for the Treatment of AML and MDS
HSMN NewsFeed - 13 Apr 2021
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
Theseus Pharmaceuticals Debuts with $100M Series B Raise to Develop Pan-Variant Kinase Inhibitors
HSMN NewsFeed - 5 Apr 2021
IceCure Medical Granted FDA Breakthrough Device Designation for ProSense(R) Cryoablation System
IceCure Medical Granted FDA Breakthrough Device Designation for ProSense(R) Cryoablation System
HSMN NewsFeed - 30 Mar 2021
Expansion of Raystation Treatment Planning System at The Inova Schar Cancer Institute
Expansion of Raystation Treatment Planning System at The Inova Schar Cancer Institute
HSMN NewsFeed - 29 Mar 2021
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
Phoenix Molecular Designs Appoints Biotech Powerhouse, Michael Varney, Ph.D., to its Advisory Board
HSMN NewsFeed - 26 Mar 2021
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
European Medicines Agency Accepts Marketing Authorization Application for Enfortumab Vedotin
HSMN NewsFeed - 23 Mar 2021
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
Poseida Therapeutics Announces Carl June, M.D., to Chair Immuno-Oncology Scientific Advisory Board
HSMN NewsFeed - 18 Mar 2021
Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
Boston Scientific Receives FDA Approval for TheraSphere(TM) Y-90 Glass Microspheres
HSMN NewsFeed - 11 Mar 2021
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
Alkermes Announces FDA Orphan Drug Designation for Nemvaleukin Alfa for Treatment of Mucosal Melanoma
